Kelly Covert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kelly Covert has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Bryan P. White
University of Oklahoma Medical Center, Oklahoma City, OK, USA
2 shared publications- Daniel B. Chastain
University of Georgia College of Pharmacy
2 shared publications - David B. Cluck
Department of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy Johnson City Tennessee USA
2 shared publications - Jessica E. Burchette
Department of Pharmacy Practice, East Tennessee State University Bill Gatton College of Pharmacy, Johnson City, TN, USA
2 shared publications - Patrick J. Tu
Department of Pharmacy, Charlie Norwood VA Medical Center , Augusta, GA
2 shared publications Benjamin A. Mardis
Department of Pharmacy Services, Medical University of South Carolina, Charleston, South Carolina
1 shared publication
Latest Publications
- 5 November 2025
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 60 (4) , 378-393
Novel Maintenance Therapies for Chronic Obstructive Pulmonary Disorder
Objective: To summarize the Global Initiative for Chronic Obstructive Lung Disease (GOLD) updates and data for novel therapies/interventions. Data sources: Articles gathered from MEDLINE, Cochrane Reviews, and PubMed databases. Package inserts for novel agents were utilized. Search terms included chronic obstructive pulmonary disorder (COPD), inhaled corticosteroids (ICS), inhaled long-acting muscarinic antagonists (LAMA), inhaled long-acting beta-2 agonists (LABA), dupilumab, ensifentrine, icenticaftor, and itepekimab. Study selection and data extraction: English-language primary literature and review articles evaluated. GOLD guidelines from 2001 to 2025 were utilized. Data synthesis: Six meta-analyses and one randomized controlled trial (RCT) favor initial LAMA/LABA combination over monocomponent agents. Three RCTs note increased ICS efficacy with blood eosinophils >300 cells/µL. One meta-analysis and 8 RCTs address vaccinations, specifically RSV and pneumococcal. Novel medications ensifentrine, dupilumab, and icenticaftor each have 2 RCTs in patients with persistent symptoms despite optimized LAMA/LABA and ICS. Itepekimab is in phase 3 studies. The CAPTURE tool has 2 RCTs validating screening patients with unrecognized COPD. Relevance to patient care and clinical practice: Identification of notable changes to optimal COPD management, including LABA/LAMA therapy, judicious ICS use, updated vaccine recommendations, and potential roles for ensifentrine and dupilumab. Conclusion and Relevance: Evidence supports LABA/LAMA with nuanced use of ICS. Several novel therapies are approved or are being studied for patients suboptimally controlled. Pharmacists can assist in medication optimization and access; however, patient-specific factors like exacerbation history, blood eosinophils, and COPD endotype must be considered. Implementing early identification screening tools such as CAPTURE should factor into patient assessment.
- 5 November 2025
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 60 (4) , 378-393
Novel Maintenance Therapies for Chronic Obstructive Pulmonary Disorder
Objective: To summarize the Global Initiative for Chronic Obstructive Lung Disease (GOLD) updates and data for novel therapies/interventions. Data sources: Articles gathered from MEDLINE, Cochrane Reviews, and PubMed databases. Package inserts for novel agents were utilized. Search terms included chronic obstructive pulmonary disorder (COPD), inhaled corticosteroids (ICS), inhaled long-acting muscarinic antagonists (LAMA), inhaled long-acting beta-2 agonists (LABA), dupilumab, ensifentrine, icenticaftor, and itepekimab. Study selection and data extraction: English-language primary literature and review articles evaluated. GOLD guidelines from 2001 to 2025 were utilized. Data synthesis: Six meta-analyses and one randomized controlled trial (RCT) favor initial LAMA/LABA combination over monocomponent agents. Three RCTs note increased ICS efficacy with blood eosinophils >300 cells/µL. One meta-analysis and 8 RCTs address vaccinations, specifically RSV and pneumococcal. Novel medications ensifentrine, dupilumab, and icenticaftor each have 2 RCTs in patients with persistent symptoms despite optimized LAMA/LABA and ICS. Itepekimab is in phase 3 studies. The CAPTURE tool has 2 RCTs validating screening patients with unrecognized COPD. Relevance to patient care and clinical practice: Identification of notable changes to optimal COPD management, including LABA/LAMA therapy, judicious ICS use, updated vaccine recommendations, and potential roles for ensifentrine and dupilumab. Conclusion and Relevance: Evidence supports LABA/LAMA with nuanced use of ICS. Several novel therapies are approved or are being studied for patients suboptimally controlled. Pharmacists can assist in medication optimization and access; however, patient-specific factors like exacerbation history, blood eosinophils, and COPD endotype must be considered. Implementing early identification screening tools such as CAPTURE should factor into patient assessment.
- 22 August 2025
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 41 (6) , 283-290
Proton Pump Inhibitor Use in Patients With Cirrhosis and Its Association With Spontaneous Bacterial Peritonitis
Background: Cirrhosis is a major cause of morbidity and mortality in the United States, with spontaneous bacterial peritonitis (SBP) being a serious complication. Established SBP risk factors include gastrointestinal bleeding and low ascitic protein, but the role of proton pump inhibitors (PPIs) remains unclear. Objective: This study evaluated the impact of PPI use on primary SBP development in hospitalized patients with cirrhosis. Additional objectives included reviewing PPI prescribing patterns and associated clinical outcomes. Methods: An institutional review board–approved, retrospective chart review was conducted on adults (≥18 years) with cirrhosis admitted for presumed SBP between June 1, 2022, and June 30, 2024. Exclusion criteria included pregnancy, incarceration, and recent or current upper gastrointestinal bleeding. Patients were grouped by PPI exposure, defined as PPI use prior to admission. The primary outcome was SBP incidence; secondary outcomes included mortality and hepatic decompensation events. Results: Eighty-one patients were included: 42 reported home PPI therapy, and 39 did not. SBP incidence was 33.3% in the PPI group versus 20.5% in the no PPI group (χ 2 = 0.249, P = 0.618). Worsening ascites occurred in 99%, encephalopathy in 42%, varices in 11%, and suspected hepatorenal syndrome in 21%. In-hospital mortality was 9.9%. PPI indications were often undocumented. Conclusion and Relevance: Although no significant association was found between home PPI use and SBP, frequent undocumented use and potential overuse of PPIs underscore the need for targeted intervention. Pharmacists are well-positioned to lead stewardship efforts by reviewing indications and minimizing unnecessary therapy to enhance safety and outcomes.
- 22 August 2025
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 41 (6) , 283-290
Proton Pump Inhibitor Use in Patients With Cirrhosis and Its Association With Spontaneous Bacterial Peritonitis
Background: Cirrhosis is a major cause of morbidity and mortality in the United States, with spontaneous bacterial peritonitis (SBP) being a serious complication. Established SBP risk factors include gastrointestinal bleeding and low ascitic protein, but the role of proton pump inhibitors (PPIs) remains unclear. Objective: This study evaluated the impact of PPI use on primary SBP development in hospitalized patients with cirrhosis. Additional objectives included reviewing PPI prescribing patterns and associated clinical outcomes. Methods: An institutional review board–approved, retrospective chart review was conducted on adults (≥18 years) with cirrhosis admitted for presumed SBP between June 1, 2022, and June 30, 2024. Exclusion criteria included pregnancy, incarceration, and recent or current upper gastrointestinal bleeding. Patients were grouped by PPI exposure, defined as PPI use prior to admission. The primary outcome was SBP incidence; secondary outcomes included mortality and hepatic decompensation events. Results: Eighty-one patients were included: 42 reported home PPI therapy, and 39 did not. SBP incidence was 33.3% in the PPI group versus 20.5% in the no PPI group (χ 2 = 0.249, P = 0.618). Worsening ascites occurred in 99%, encephalopathy in 42%, varices in 11%, and suspected hepatorenal syndrome in 21%. In-hospital mortality was 9.9%. PPI indications were often undocumented. Conclusion and Relevance: Although no significant association was found between home PPI use and SBP, frequent undocumented use and potential overuse of PPIs underscore the need for targeted intervention. Pharmacists are well-positioned to lead stewardship efforts by reviewing indications and minimizing unnecessary therapy to enhance safety and outcomes.
- 7 December 2024
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 59 (8) , 743-757
Pivmecillinam for Uncomplicated Acute Cystitis: A Contemporary Review
Objective: To review the evidence and discuss use of pivmecillinam in uncomplicated acute cystitis. Data sources: A literature search was conducted utilizing PubMed (from 2000 through August 2024) and ClinicalTrials.gov. Medical Subject Headings (MeSH) terms, such as mecillinam or pivmecillinam and urinary tract infections, were utilized. Additional references were identified by reviewing literature citations. Study selection and data extraction: Articles were limited to English language publications evaluating the efficacy or safety of pivmecillinam for urinary tract infections (UTIs) in adult populations. Data synthesis: Data from 6 randomized controlled trials support pivmecillinam for acute uncomplicated cystitis at doses of 200 to 400 mg 3 times daily for 3 to 7 days, with more consistent clinical and bacteriologic cure observed with 400 mg doses and longer therapy durations. Clinical evaluation of 400 mg 2 to 3 times daily is available with use more common in non–US Food and Drug Administration (FDA)-approved populations, such as men, pregnancy, and multidrug resistant infections. There are limited data supporting pivmecillinam for pyelonephritis; routine use is cautioned until further clinical data are available. Relevance to patient care and clinical practice in comparison with existing drugs: As resistance to first-line antimicrobials rises, the need for safe and effective treatment options remains high. Pivmecillinam represents a new therapeutic option available in the United States for outpatient management of uncomplicated acute cystitis. Conclusion: Pivmecillinam could be a key agent for uncomplicated acute cystitis. Utilization will likely be cost driven, but the promise of low resistance encourages the place in therapy when other agents are not susceptible to infecting uropathogens.
- 7 December 2024
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 59 (8) , 743-757
Pivmecillinam for Uncomplicated Acute Cystitis: A Contemporary Review
Objective: To review the evidence and discuss use of pivmecillinam in uncomplicated acute cystitis. Data sources: A literature search was conducted utilizing PubMed (from 2000 through August 2024) and ClinicalTrials.gov. Medical Subject Headings (MeSH) terms, such as mecillinam or pivmecillinam and urinary tract infections, were utilized. Additional references were identified by reviewing literature citations. Study selection and data extraction: Articles were limited to English language publications evaluating the efficacy or safety of pivmecillinam for urinary tract infections (UTIs) in adult populations. Data synthesis: Data from 6 randomized controlled trials support pivmecillinam for acute uncomplicated cystitis at doses of 200 to 400 mg 3 times daily for 3 to 7 days, with more consistent clinical and bacteriologic cure observed with 400 mg doses and longer therapy durations. Clinical evaluation of 400 mg 2 to 3 times daily is available with use more common in non–US Food and Drug Administration (FDA)-approved populations, such as men, pregnancy, and multidrug resistant infections. There are limited data supporting pivmecillinam for pyelonephritis; routine use is cautioned until further clinical data are available. Relevance to patient care and clinical practice in comparison with existing drugs: As resistance to first-line antimicrobials rises, the need for safe and effective treatment options remains high. Pivmecillinam represents a new therapeutic option available in the United States for outpatient management of uncomplicated acute cystitis. Conclusion: Pivmecillinam could be a key agent for uncomplicated acute cystitis. Utilization will likely be cost driven, but the promise of low resistance encourages the place in therapy when other agents are not susceptible to infecting uropathogens.
- 22 March 2023
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 57 (11) , 1312-1327
Therapeutic Options for Adult Patients With Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Narrative Review
Objective: To compare the efficacy of antimicrobial therapies used in the management of persistent methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Data Sources: A literature search using the PubMed database (inception to December 2022) was conducted using the search terms “ Staphylococcus aureus bacteremia,” “methicillin-susceptible Staphylococcus aureus bacteremia,” “persistent methicillin-susceptible Staphylococcus aureus bacteremia,” and “refractory methicillin-susceptible Staphylococcus aureus bacteremia .” In addition, therapeutic agents which could be used as treatment for MSSA including “nafcillin,” “oxacillin,” “cefazolin,” “ceftaroline,” “gentamicin,” “rifampin,” and “daptomycin” were also combined with the aforementioned search terms to capture data using these agents. Study Selection/Data Extraction: Clinical data were limited to those published in the English language. Articles and abstracts were considered for inclusion in addition to ongoing trials identified through ClinicalTrials.gov. Data Synthesis: A total of 78 articles were reviewed including 17 in vitro or animal model studies and 39 studies including patient data. The remaining 22 articles included guidelines, review articles, and editorials. Recent data evaluating use of dual β-lactam regimens for persistent MSSA bacteremia were limited to 8 case reports or case series. Relevance to Patient Care and Clinical Practice: At present, there is little guidance on how to best manage patients with persistent MSSA bacteremia. This narrative review collates the available data to assist clinicians in selecting the best possible antimicrobial regimen when facing this clinical conundrum. Conclusions: Modification of antimicrobial therapy, in conjunction with source control and infectious diseases consultation, may all be necessary to sterilize blood cultures in patients with persistent MSSA bacteremia.
- 22 March 2023
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 57 (11) , 1312-1327
Therapeutic Options for Adult Patients With Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Narrative Review
Objective: To compare the efficacy of antimicrobial therapies used in the management of persistent methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Data Sources: A literature search using the PubMed database (inception to December 2022) was conducted using the search terms “ Staphylococcus aureus bacteremia,” “methicillin-susceptible Staphylococcus aureus bacteremia,” “persistent methicillin-susceptible Staphylococcus aureus bacteremia,” and “refractory methicillin-susceptible Staphylococcus aureus bacteremia .” In addition, therapeutic agents which could be used as treatment for MSSA including “nafcillin,” “oxacillin,” “cefazolin,” “ceftaroline,” “gentamicin,” “rifampin,” and “daptomycin” were also combined with the aforementioned search terms to capture data using these agents. Study Selection/Data Extraction: Clinical data were limited to those published in the English language. Articles and abstracts were considered for inclusion in addition to ongoing trials identified through ClinicalTrials.gov. Data Synthesis: A total of 78 articles were reviewed including 17 in vitro or animal model studies and 39 studies including patient data. The remaining 22 articles included guidelines, review articles, and editorials. Recent data evaluating use of dual β-lactam regimens for persistent MSSA bacteremia were limited to 8 case reports or case series. Relevance to Patient Care and Clinical Practice: At present, there is little guidance on how to best manage patients with persistent MSSA bacteremia. This narrative review collates the available data to assist clinicians in selecting the best possible antimicrobial regimen when facing this clinical conundrum. Conclusions: Modification of antimicrobial therapy, in conjunction with source control and infectious diseases consultation, may all be necessary to sterilize blood cultures in patients with persistent MSSA bacteremia.
- Open Access
- 5 December 2020
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (2) , 277-285
Utility of the respiratory viral panel as an antimicrobial stewardship tool
What is Known and Objective The development of rapid diagnostics has revolutionized antimicrobial stewardship with efforts targeting earlier de‐escalation or discontinuation of antibiotics. The respiratory viral panel (RVP) is one tool quickly able to detect common viral and bacterial pathogens using polymerase chain reaction technology. Utility may be further enhanced in conjunction with procalcitonin (PCT). However, the optimal use of the RVP to the clinical pharmacist in the treatment of community‐acquired respiratory infections remains unclear. Methods The purpose of this guide is to review the available literature regarding the impact of the RVP with and without procalcitonin on antimicrobial stewardship efforts and to provide guidance on how to use each of these tools. Results and Discussion In total, 13 studies were included, 5 of which utilized PCT in conjunction with RVP and 8 of which did not use PCT. The majority of studies were retrospective in nature, and the most common outcomes evaluated were antibiotic days of therapy (DOT) and time to antibiotic discontinuation. What is New and Conclusion After review, RVP alone has limited value to antimicrobial stewardship; however, when used in conjunction with procalcitonin, RVP has the potential to reduce antibiotic use and duration.
- 5 December 2020
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (2) , 277-285
Open AccessUtility of the respiratory viral panel as an antimicrobial stewardship tool
What is Known and Objective The development of rapid diagnostics has revolutionized antimicrobial stewardship with efforts targeting earlier de‐escalation or discontinuation of antibiotics. The respiratory viral panel (RVP) is one tool quickly able to detect common viral and bacterial pathogens using polymerase chain reaction technology. Utility may be further enhanced in conjunction with procalcitonin (PCT). However, the optimal use of the RVP to the clinical pharmacist in the treatment of community‐acquired respiratory infections remains unclear. Methods The purpose of this guide is to review the available literature regarding the impact of the RVP with and without procalcitonin on antimicrobial stewardship efforts and to provide guidance on how to use each of these tools. Results and Discussion In total, 13 studies were included, 5 of which utilized PCT in conjunction with RVP and 8 of which did not use PCT. The majority of studies were retrospective in nature, and the most common outcomes evaluated were antibiotic days of therapy (DOT) and time to antibiotic discontinuation. What is New and Conclusion After review, RVP alone has limited value to antimicrobial stewardship; however, when used in conjunction with procalcitonin, RVP has the potential to reduce antibiotic use and duration.
- 21 September 2020
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 3 (8) , 1434-1436
Evaluation of the reading level of commonly used medication‐related patient education sources
- 21 September 2020
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 3 (8) , 1434-1436
Evaluation of the reading level of commonly used medication‐related patient education sources
- Open Access
- 18 August 2020
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 45 (6) , 1253-1263
Vancomycin plus piperacillin/tazobactam and acute kidney injury risk: A review of the literature
What is known and objective Acute kidney injury is a devastating consequence observed with antibiotic therapy. The objective of this review was to summarize available data regarding the rates of acute kidney injury with vancomycin plus piperacillin/tazobactam compared to other beta‐lactam combinations. Methods A PubMed search from 2011 to May 2020 was conducted using the following search terms: vancomycin AND piperacillin/tazobactam AND acute kidney injury. Additional references were identified from a review of citations. Articles evaluating exclusively paediatric patients and articles evaluating vancomycin monotherapy as the comparator group were excluded. Case reports and case series were also excluded. Results and discussion There were 18 studies included. Ten studies adjusted for potential confounders of acute kidney injury. Fourteen retrospective studies, one prospective study and three meta‐analyses found the combination of vancomycin/piperacillin/tazobactam to be associated with a higher rate of acute kidney injury than the comparator group(s). What is new and conclusion Although there are data to support that the combination of vancomycin plus piperacillin‐tazobactam increases the risk of acute kidney, much of the data come from small retrospective studies with variable adjustment for confounders. Furthermore, study heterogeneity on inclusion criteria and evaluation of long‐term outcomes should be cautiously interpreted. Finally, additional data suggest that the risk of acute kidney injury seems to be minimized with shorter courses of therapy. Without prospective studies available, antimicrobial stewardship efforts should continue to target reducing broad‐spectrum regimens, often limiting the need for long‐term vancomycin/piperacillin/tazobactam combination.
- 18 August 2020
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 45 (6) , 1253-1263
Open AccessVancomycin plus piperacillin/tazobactam and acute kidney injury risk: A review of the literature
What is known and objective Acute kidney injury is a devastating consequence observed with antibiotic therapy. The objective of this review was to summarize available data regarding the rates of acute kidney injury with vancomycin plus piperacillin/tazobactam compared to other beta‐lactam combinations. Methods A PubMed search from 2011 to May 2020 was conducted using the following search terms: vancomycin AND piperacillin/tazobactam AND acute kidney injury. Additional references were identified from a review of citations. Articles evaluating exclusively paediatric patients and articles evaluating vancomycin monotherapy as the comparator group were excluded. Case reports and case series were also excluded. Results and discussion There were 18 studies included. Ten studies adjusted for potential confounders of acute kidney injury. Fourteen retrospective studies, one prospective study and three meta‐analyses found the combination of vancomycin/piperacillin/tazobactam to be associated with a higher rate of acute kidney injury than the comparator group(s). What is new and conclusion Although there are data to support that the combination of vancomycin plus piperacillin‐tazobactam increases the risk of acute kidney, much of the data come from small retrospective studies with variable adjustment for confounders. Furthermore, study heterogeneity on inclusion criteria and evaluation of long‐term outcomes should be cautiously interpreted. Finally, additional data suggest that the risk of acute kidney injury seems to be minimized with shorter courses of therapy. Without prospective studies available, antimicrobial stewardship efforts should continue to target reducing broad‐spectrum regimens, often limiting the need for long‐term vancomycin/piperacillin/tazobactam combination.
- 19 May 2020
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 77 (11) , 865-876
Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations
Purpose: To review the literature on treatment of venous thromboembolism (VTE) and prevention of cardioembolic stroke with direct-acting oral anticoagulants (DOACs) in low- and high-body-weight patients and to make recommendations regarding agent selection and dosing in these patient populations. Summary: The selection and optimal dosing of DOACs in low- and high-body-weight patients has not yet been fully elucidated by clinical trials; however, evidence suggests that issues of both safety and efficacy in patients at the extremes of body weight may warrant careful consideration when selecting a DOAC for such patients. This review provides a thorough discussion of the use of DOACs in the treatment of VTE and prevention of cardioembolic stroke in patients at the extremes of body weight and provides guidance regarding agent selection. Conclusion: While the published evidence on use of DOACs in patients at extremes of body weight is sparse, apixaban and rivaroxaban appear to have the most favorable safety and efficacy profiles. Edoxaban and dabigatran should be avoided.
- 19 May 2020
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 77 (11) , 865-876
Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations
Purpose: To review the literature on treatment of venous thromboembolism (VTE) and prevention of cardioembolic stroke with direct-acting oral anticoagulants (DOACs) in low- and high-body-weight patients and to make recommendations regarding agent selection and dosing in these patient populations. Summary: The selection and optimal dosing of DOACs in low- and high-body-weight patients has not yet been fully elucidated by clinical trials; however, evidence suggests that issues of both safety and efficacy in patients at the extremes of body weight may warrant careful consideration when selecting a DOAC for such patients. This review provides a thorough discussion of the use of DOACs in the treatment of VTE and prevention of cardioembolic stroke in patients at the extremes of body weight and provides guidance regarding agent selection. Conclusion: While the published evidence on use of DOACs in patients at extremes of body weight is sparse, apixaban and rivaroxaban appear to have the most favorable safety and efficacy profiles. Edoxaban and dabigatran should be avoided.
- 20 December 2016
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 37 (2) , 159-169
Development of a Predictive Model for Drug‐Related Problems in Kidney Transplant Recipients
Study Objective: Drug‐related problems (DRPs) are associated with increased rates of infection, rejection, and graft loss in kidney transplant recipients. This study aimed to develop a model to predict which patients are at highest risk of DRPs to streamline pharmacists’ workflow in a chronic kidney transplant clinic.Design: Prospective observational study.Setting: Chronic kidney transplant clinic at a large, tertiary care, academic hospital.Patients: Two hundred thirty‐seven adults seen in the kidney transplant clinic between September 16, 2015, and November 30, 2015, who were at least 90 days posttransplantation at the time of their clinic visit.Measurements and Main Results: Prospective data detailing DRPs and a survey assessing baseline characteristics and patient‐related outcomes were used to generate a predictive model to identify patients at risk of having six or more DRPs; the cutoff of six DRPs provided a threshold for identifying a subset of high‐risk patients on whom the transplant pharmacists could focus their efforts. DRPs were categorized as nonadherence, overdosing or underdosing, duplication of therapy, preventable adverse drug reaction, missing medication, erroneous medication, conflicting provider information, undermonitoring or lack of monitoring, and wrong medication received. In total, 865 unique DRPs were identified, and the most common were erroneous medication, missing medication, and nonadherence, accounting for 38%, 21%, and 16% of the DRPs, respectively. A nine‐variable model with a sensitivity of 62.5% and specificity of 66.7% (area under the receiver operating characteristic curve of 0.720) was developed to identify patients at risk of having six or more DRPs. The model included the following variables: age, Medicaid for prescription insurance, current employment status, medication affordability, difficulty or lack of difficulty obtaining medications from the pharmacy, negative impact of medications on quality of life, medication nonadherence, poor rating of current health status, and moderate or poor medication understanding.Conclusion: These results demonstrated that a straightforward, 5‐minute survey completed by renal transplant recipients prior to their clinic visit may be capable of effectively determining those at risk of having six or more DRPs, potentially allowing use as a screening tool for transplant pharmacists’ workflow prioritization. External validation is needed before this tool can be used in the outpatient setting.
- 20 December 2016
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 37 (2) , 159-169
Development of a Predictive Model for Drug‐Related Problems in Kidney Transplant Recipients
Study Objective: Drug‐related problems (DRPs) are associated with increased rates of infection, rejection, and graft loss in kidney transplant recipients. This study aimed to develop a model to predict which patients are at highest risk of DRPs to streamline pharmacists’ workflow in a chronic kidney transplant clinic.Design: Prospective observational study.Setting: Chronic kidney transplant clinic at a large, tertiary care, academic hospital.Patients: Two hundred thirty‐seven adults seen in the kidney transplant clinic between September 16, 2015, and November 30, 2015, who were at least 90 days posttransplantation at the time of their clinic visit.Measurements and Main Results: Prospective data detailing DRPs and a survey assessing baseline characteristics and patient‐related outcomes were used to generate a predictive model to identify patients at risk of having six or more DRPs; the cutoff of six DRPs provided a threshold for identifying a subset of high‐risk patients on whom the transplant pharmacists could focus their efforts. DRPs were categorized as nonadherence, overdosing or underdosing, duplication of therapy, preventable adverse drug reaction, missing medication, erroneous medication, conflicting provider information, undermonitoring or lack of monitoring, and wrong medication received. In total, 865 unique DRPs were identified, and the most common were erroneous medication, missing medication, and nonadherence, accounting for 38%, 21%, and 16% of the DRPs, respectively. A nine‐variable model with a sensitivity of 62.5% and specificity of 66.7% (area under the receiver operating characteristic curve of 0.720) was developed to identify patients at risk of having six or more DRPs. The model included the following variables: age, Medicaid for prescription insurance, current employment status, medication affordability, difficulty or lack of difficulty obtaining medications from the pharmacy, negative impact of medications on quality of life, medication nonadherence, poor rating of current health status, and moderate or poor medication understanding.Conclusion: These results demonstrated that a straightforward, 5‐minute survey completed by renal transplant recipients prior to their clinic visit may be capable of effectively determining those at risk of having six or more DRPs, potentially allowing use as a screening tool for transplant pharmacists’ workflow prioritization. External validation is needed before this tool can be used in the outpatient setting.